Full View

Breaking the cycle: targeting of NDRG1 to inhibit bi‐directional oncogenic cross‐talk between pancreatic cancer and stroma

B Geleta, KC Park, PJ Jansson, S Sahni… - The FASEB …, 2021 - Wiley Online Library
Pancreatic cancer (PaCa) is characterized by dense stroma that hinders treatment efficacy,
with pancreatic stellate cells (PSCs) being a major contributor to this stromal barrier and …
被引用次数：32 相关文章

Breaking the cycle: Targeting of NDRG1 to inhibit bi-directional oncogenic cross-talk between pancreatic cancer and stroma

B Geleta, KC Park, PJ Jansson… - … publication of the …, 2021 - pubmed.ncbi.nlm.nih.gov
Pancreatic cancer (PaCa) is characterized by dense stroma that hinders treatment efficacy,
with pancreatic stellate cells (PSCs) being a major contributor to this stromal barrier and …

[引用][C] Breaking the cycle: Targeting of NDRG1 to inhibit bi‐directional oncogenic cross‐talk between pancreatic cancer and stroma

B Geleta, KC Park, PJ Jansson, S Sahni, S Maleki… - The FASEB …, 2021 - cir.nii.ac.jp
Breaking the cycle: Targeting of NDRG1 to inhibit bi‐directional oncogenic cross‐talk between
pancreatic cancer and stroma | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ …

Breaking the cycle: Targeting of NDRG1 to inhibit bi-directional oncogenic cross-talk between pancreatic cancer and stroma.

B Geleta, KC Park, PJ Jansson, S Sahni… - … : Official Publication of …, 2021 - europepmc.org
Pancreatic cancer (PaCa) is characterized by dense stroma that hinders treatment efficacy,
with pancreatic stellate cells (PSCs) being a major contributor to this stromal barrier and …